# The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty

> **NCT01634321** · PHASE4 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 63 (actual)

## Conditions studied

- Central Precocious Puberty

## Interventions

- **DRUG:** Luphere depot 3.75mg(Leuprolide acetate 3.75mg)

## Key facts

- **NCT ID:** NCT01634321
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2014-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634321, "The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01634321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*